A Phase 4 interventional study of Enoxaparin in Deep Vein Thrombosis, Venous Thrombosis and Adverse Effect of Anticoagulants, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2015-11-03.
Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing enoxaparin in Venous Thrombosis — 3 open to participants now, 3 under way, 1 of them phase 3. Enoxaparin · Venous Thrombosis.
Among the 42 studies testing enoxaparin in Venous Thrombosis, this one is the 17th largest by enrollment, is one of 3 that started in 2011, is one of 15 in phase 4, and was the 14th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →3 of the 42 studies testing enoxaparin in Venous Thrombosis are open now, in 2 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Yale University · Sites in United States
Ages up to 17
Oregon Health and Science University · Sites in United States
Ages 15–100
By country, each count listing its studies:
Enoxaparin: first FDA approval 1993 (LOVENOX (PRESERVATIVE FREE)), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 15
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is close to the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 114 across the 42 interventional studies. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 42 have an industry lead sponsor. The 10 most frequent:
Les Laboratoires des Médicaments Stériles is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Les Laboratoires des Médicaments Stériles has 1 study filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing enoxaparin in Venous Thrombosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing enoxaparin in Venous Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of the study are:
o Objective ultrasound: Determine the presence or absence of subclinical DVT in practicing ultrasound-Doppler Day7 and Day35, patients who underwent TKA or THA
o Clinical objective To evaluate the efficacy and tolerability clinical Enox ® in these patients compared with the original drug Lovenox ®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient under lovenox 4000 IU
Drug: Enoxaparin
patients under Enoxa 4000 IU
Drug: Enoxaparin
patients undergoing total knee replacement
patient undergoing total knee replacement
enoxaparin 4000 IU 1 injection/day in subcutaneous.
Presence or absence of ultrasound findings in favor of asymptomatic DVT
After orthopedic surgery, patients are put under LMWH thromboprophylaxis based but some patients may be carrying an asymptomatic DVT. so we'll try the distal venous thrombosis rate in these patients using Doppler ultrasound.
Time frame: Day 7 and 35
To evaluate the efficacy and tolerability clinical Enox ® in these patients.
Criteria for evaluating the effectiveness of Enox ®: * Onset or without clinical signs of deep vein thrombosis in clinical postoperative * Onset or without clinical signs of pulmonary embolism after surgery
Time frame: 3 months
The record gives a start of Mar 2011, a primary completion of Jul 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enoxaparin
Les Laboratoires des Médicaments Stériles